In 2014, a stool DNA test, Cologuard, was approved by FDA for CRC screening, which also detected two methylated DNA markers (BMP3 and NDRG4), and combined with seven KRAS mutation sites and an immunochemical assay for human hemoglobin 25. This evidence concerns the gene BMP3 and colorectal carcinoma.